Inventor
Steven W. Andrews
Inventor
Boulder, CO, US
Overview
Patents· 87 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes25%
C07DHeterocyclic compounds23%
Y02ATechnologies for adaptation to climate change11%
C07CAcyclic or carbocyclic compounds6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C07KPeptides1%
Y02PClimate change mitigation technologies in the production or processing of goods0%
PatentTitleYear
10,966,985Macrocyclic compounds as ROS1 kinase inhibitors202110,953,005Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors202110,907,215Point mutations in TRK inhibitor-resistant cancer and methods relating to the same202110,889,589Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain202110,881,652Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors202110,835,5331 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor202010,774,085Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds202010,766,8812-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases202010,758,542Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors202010,724,102Point mutations in TRK inhibitor-resistant cancer and methods relating to the same202010,688,100Macrocylic compounds as ROS1 kinase inhibitors202010,655,186Point mutations in TRK inhibitor-resistant cancer and methods relating to the same202010,647,730Macrocyclic compounds as TRK kinase inhibitors202010,590,139Method of treatment using substituted imidazo[1,2b]pyridazine compounds202010,555,944Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors202010,441,581Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,378,068Point mutations in TRK inhibitor-resistant cancer and methods relating to the same201910,370,727Point mutations in TRK inhibitor-resistant cancer and methods relating to the same201910,351,575Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain201910,323,022Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors201910,251,889Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors201910,208,0242-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases201910,172,851Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,174,027Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors201910,172,845Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,174,028Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,144,734Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201810,137,124Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors201810,138,243Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors201810,112,942Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201810,047,097Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds201810,023,570Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201810,011,604Method of treatment using substituted imidazo[1,2b]pyridazine compounds201810,005,783Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds20189,902,741'Macrocyclic compounds as TRK kinase inhibitors'20189,878,997'Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors'20189,840,519'Macrocyclic compounds as TRK kinase inhibitors'20179,828,360Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors20179,796,724'Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors'20179,796,723'Method of treatment using substituted imidazo[1,2b]pyridazine compounds'20179,795,611'Method of treatment using substituted imidazo[1,2b]pyridazine compounds'20179,790,178'Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors'20179,790,210'N-(monocyclic aryl),N\'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors'20179,782,415'Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors'20179,750,744'Macrocyclic compounds as Trk kinase inhibitors'20179,718,822'Macrocyclic compounds as Trk kinase inhibitors'20179,682,979'Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors'20179,676,783'Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds'20179,562,055'Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors'20179,493,476'Macrocyclic compounds as trk kinase inhibitors'20169,447,104'Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds'20169,227,975'Method of treatment using substituted imidazo[1,2B]pyridazine compounds'20169,127,013'Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds'20158,933,084'Macrocyclic compounds as Trk kinase inhibitors'20158,865,726'Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors'20148,865,698'Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds'20148,791,123'Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors'20148,513,263'Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors'20138,299,021'Macrocyclic inhibitors of hepatitis C virus replication'20128,119,592'Compounds and methods for inhibiting hepatitis C viral replication'20128,017,655'Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'20117,932,277'Peptide inhibitors of hepatitis C virus replication'20117,829,665'Macrocyclic inhibitors of hepatitis C virus replication'20107,781,474'Inhibitors of hepatitis C virus replication'20107,531,665'Kinase inhibitors for the treatment of disease'20097,491,794'Macrocyclic compounds as inhibitors of viral replication'20097,414,054'3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors'20087,393,870'3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors'20087,351,825'Cyclopropane compounds and pharmaceutical use thereof'20087,098,236'3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors'20067,060,844'(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors'20067,015,220'3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors'20067,005,444'3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors'20066,765,012'3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors'20046,747,025'Kinase inhibitors for the treatment of disease'20046,699,863'Kinase inhibitors for the treatment of disease'20046,559,173'3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors'20036,541,504'(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors'20036,403,649'Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents'20026,395,787'Ocular hypotensive lipids'20026,258,844'Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents'20015,688,819'Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'19975,607,978'Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'19975,486,540'Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents'19965,457,131'Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents'19955,387,608'Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents'19955,352,708'Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'1994Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1994–2011Patents assigned to ALLERGAN INC (18)· patent assignee history
1994–2011Based in Irvine, CA, US· patent location history
1997–2002Based in Rancho Santa Margarita, CA, US· patent location history
2003–2021Based in Longmont, CO, US· patent location history
2009–2012Patents assigned to INTERMUNE INC (6)· patent assignee history
2011–2021Patents assigned to ARRAY BIOPHARMA INC (59)· patent assignee history
2012–2017Patents assigned to HAAS JULIA (6)· patent assignee history
2012–2017Patents assigned to JIANG YUTONG (6)· patent assignee history
2012Based in Langmont, CO, US· patent location history
2013–2021Based in Boulder, CO, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ARRAY BIOPHARMA INC | 59 | 2011–2021 |
| ALLERGAN INC | 18 | 1994–2011 |
| HAAS JULIA | 6 | 2012–2017 |
| INTERMUNE INC | 6 | 2009–2012 |
| JIANG YUTONG | 6 | 2012–2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| Boulder, CO, US | 57 | 2013–2021 |
| Longmont, CO, US | 19 | 2003–2021 |
| Irvine, California, US | 6 | 1994–2011 |
| Rancho Santa Margarita, California, US | 4 | 1997–2002 |
| Langmont, CO, US | 1 | 2012 |